Body mass index and its association with COVID-19 clinical outcomes: Findings from the Philippine CORONA study.
Body mass index
COVID-19
Obesity
Outcomes
SARS-CoV-2
Underweight
Journal
Clinical nutrition ESPEN
ISSN: 2405-4577
Titre abrégé: Clin Nutr ESPEN
Pays: England
ID NLM: 101654592
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
18
08
2021
revised:
04
02
2022
accepted:
11
03
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
1
6
2022
Statut:
ppublish
Résumé
To explore the association between body mass index (BMI) and adverse outcomes in a large cohort of patients with coronavirus disease 2019 (COVID-19). This is a secondary analysis of a 37-site, nationwide, multicenter, retrospective cohort study that investigated the clinical and neurological outcomes of adult patients with confirmed COVID-19 admitted from February to December 15, 2020. We analyzed 4,463 patients with BMI and outcome data. A total of 790 (17.7%) and 710 (15.9%) had the primary outcome of in-hospital mortality and need for invasive mechanical ventilation (IMV), respectively. There was no significant association between WHO BMI groups and these outcomes. Using Asia-Pacific cutoffs showed a significant association between obesity and in-hospital mortality risk (P = 0.012). Being underweight was an independent predictor of prolonged IMV requirement regardless of BMI criteria used (P < 0.01). Obesity correlated with the need for intensive care unit admission using Asia-Pacific cutoffs (P = 0.029). There was a significant association between any BMI abnormality and odds of severe/critical COVID-19 (P < 0.05). Obese patients with concomitant acute neurological presentation/diagnosis during their COVID-19 admission were shown to have lower odds of neurologic recovery (P < 0.05). We found BMI abnormalities to be associated with several adverse clinical and neurologic outcomes, although such associations may be more evident with the use of race-specific BMI criteria.
Sections du résumé
BACKGROUND AND AIMS
To explore the association between body mass index (BMI) and adverse outcomes in a large cohort of patients with coronavirus disease 2019 (COVID-19).
METHODS
This is a secondary analysis of a 37-site, nationwide, multicenter, retrospective cohort study that investigated the clinical and neurological outcomes of adult patients with confirmed COVID-19 admitted from February to December 15, 2020.
RESULTS
We analyzed 4,463 patients with BMI and outcome data. A total of 790 (17.7%) and 710 (15.9%) had the primary outcome of in-hospital mortality and need for invasive mechanical ventilation (IMV), respectively. There was no significant association between WHO BMI groups and these outcomes. Using Asia-Pacific cutoffs showed a significant association between obesity and in-hospital mortality risk (P = 0.012). Being underweight was an independent predictor of prolonged IMV requirement regardless of BMI criteria used (P < 0.01). Obesity correlated with the need for intensive care unit admission using Asia-Pacific cutoffs (P = 0.029). There was a significant association between any BMI abnormality and odds of severe/critical COVID-19 (P < 0.05). Obese patients with concomitant acute neurological presentation/diagnosis during their COVID-19 admission were shown to have lower odds of neurologic recovery (P < 0.05).
CONCLUSIONS
We found BMI abnormalities to be associated with several adverse clinical and neurologic outcomes, although such associations may be more evident with the use of race-specific BMI criteria.
Identifiants
pubmed: 35623845
pii: S2405-4577(22)00187-5
doi: 10.1016/j.clnesp.2022.03.013
pmc: PMC8968152
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
402-410Informations de copyright
Copyright © 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors have stated explicitly that there are no conflicts of interest in connection with this article.
Références
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Obesity (Silver Spring). 2020 Sep;28(9):1606-1612
pubmed: 32470210
J Neural Transm (Vienna). 2021 Nov;128(11):1687-1703
pubmed: 34448930
Int J Obes (Lond). 2021 Mar;45(3):687-694
pubmed: 33495522
Obesity (Silver Spring). 2021 Feb;29(2):279-284
pubmed: 33128848
Int J Obes (Lond). 2021 Mar;45(3):700-705
pubmed: 33221825
Ann Intern Med. 2020 Nov 17;173(10):782-790
pubmed: 32726151
Ann Intern Med. 2020 Nov 17;173(10):855-858
pubmed: 32628537
Can J Neurol Sci. 2021 Jan;48(1):66-76
pubmed: 32665054
Obesity (Silver Spring). 2020 Dec;28(12):2282-2289
pubmed: 32815621
Front Endocrinol (Lausanne). 2020 Aug 14;11:562
pubmed: 32922366
Obes Rev. 2009 Mar;10(2):154-67
pubmed: 19021872
Clin Infect Dis. 2021 Oct 5;73(7):e1855-e1862
pubmed: 32841322
PLoS One. 2021 Feb 16;16(2):e0247023
pubmed: 33592042
BMJ Open. 2020 Nov 30;10(11):e040944
pubmed: 33257488
Int J Equity Health. 2020 Aug 12;19(1):137
pubmed: 32787914
Neurocrit Care. 2021 Jun;34(3):1062-1071
pubmed: 32661794
Cleve Clin J Med. 2020 Nov 23;87(12):729-734
pubmed: 32847818
Obesity (Silver Spring). 2021 May;29(5):900-908
pubmed: 33336934
Clin Infect Dis. 2009 Oct 1;49(7):1096-102
pubmed: 19725790
Crit Care Med. 2020 Nov;48(11):e1097-e1101
pubmed: 33045152
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Nutr Metab Cardiovasc Dis. 2020 Oct 30;30(11):1920-1925
pubmed: 32988724
BMC Infect Dis. 2021 Feb 5;21(1):147
pubmed: 33546633
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Clin Nutr ESPEN. 2021 Apr;42:98-104
pubmed: 33745628
JAMA Netw Open. 2020 Feb 5;3(2):e1921520
pubmed: 32074293
Diabetes Metab. 2021 Mar;47(2):101178
pubmed: 32738402
Lancet. 2020 Jan 4;395(10217):65-74
pubmed: 31852602
Circulation. 2021 Jan 12;143(2):135-144
pubmed: 33200947